Clyra Medical Technologies announced that it has received test results showing that its proprietary copper iodine antimicrobial and antiviral product, Clyraguard, successfully inactivated the COVID-19 coronavirus (SARS-CoV-2 virus).
Testing was conducted by the laboratory of Slobodan Paessler, DVM, PhD, a distinguished University Chair in Biodefense at The University of Texas Medical Branch at Galveston. The results of the laboratory study are expected to be published in a formal scientific paper as soon as possible.
Clyraguard is a personal protective spray designed to help prevent cross contamination of the personal protective equipment worn by front-line healthcare workers by the SARS-CoV-2 coronavirus, the cause of COVID-19 disease. Registered with the FDA as a Class I general purpose disinfectant, Clyraguard features an extremely high antimicrobial efficacy at 99.999% kill rate (complete inactivation), and the recent testing showed it inactivates the COVID-19 coronavirus below the limits of detection of the testing model.
This clear, colorless and odorless product has been extensively tested and found to be non-irritating, non-sensitizing, non-toxic, and non-staining as well as a host of other product features.*
Clyra Medical president Steve Harrison commented, “Dr. Paessler and his team at the Galveston National Lab are experts in this area and the entire organization is highly responsive to help identify solutions in this time of crisis.”